Lilly and Roche expressed their criticism of the draft guidance from the U.S. Centers for Medicare & Medicaid Services (CMS) for Biogen’s Alzheimer’s drug Aduhelm (aducanumab).
Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.
President Joe Biden on Aug. 12 called on U.S. lawmakers to enact legislation aimed at lowering drug prices, including allowing Medicare to negotiate drug prices and imposing penalties on drugmakers that hike prices faster than inflation.
White House Reverses Course, Approves New FDA COVID-19 Vaccine Guidelines Published: Oct. 7, 2020 By Alex Keown BioSpace The White House has reversed its position on new vaccine guidelines proposed […]
President Donald Trump signed a new executive order aimed at lowering drug prices in the United States by linking them to those of other nations and expanding the scope of a July 2020 action.
In an aim to create a strong domestic supply chain, President Donald Trump signed an Executive Order that calls for federal agencies to purchase “essential drugs” and medical supplies that are produced in the United States, rather than from abroad as is the current practice.
A meeting with top pharmaceutical executives that President Donald Trump promised wasn called off, a White House official said.
As the number of diagnosed cases of COVID-19 continues to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization.
The Trump administration secured commitments from top pharmaceutical companies to work together to develop a vaccine and treatments to fight the coronavirus.
As the J.P. Morgan Healthcare Conference continues to roll on with companies showcasing their pipelines and business plans, negative reports about the host city San Francisco have been made.
